The 2022–2023 National Drug Strategy Household Survey was conducted in two phases, the first between July and December of 2022 and the second between March and May 2023. The survey examines current awareness of attitudes and behaviours toward drugs and drug problems within the Australian community, focusing on respondents' personal attitudes toward drugs, knowledge of drugs and drug histories. The survey included questions regarding respondents' personal drug and alcohol experience and behaviour, opinions on drug policy and legislation, availability of drugs and alcohol, injury and harm from drugs and alcohol, and attitudes towards the use of alcohol and other drugs. The drugs covered included: tobacco/cigarettes, e-cigarettes/vapes, alcohol, kava, pain-killers/pain-relievers and opioids, tranquillisers, heroin, methadone, inhalants, ketamine, GHB, ecstasy, hallucinogens, cocaine, methamphetamine and amphetamine, pharmaceutical stimulants, cannabis/marijuana, synthetic cannabis, other psychoactive substances, and steroids. Demographic and background variables included: state of residence, age, gender, marital status, self-assessed health status, sexuality, Indigenous status, country of birth, language spoken at home, employment status, occupation, level of education, income, index of socio-economic advantage and disadvantage, remoteness area and household composition.

The 2019 National Drug Strategy Household Survey was conducted between April and September of 2019 and examines current awareness of attitudes and behaviours toward drugs and drug problems within the Australian community, focussing on respondents' personal attitudes toward drugs, knowledge of drugs and drug histories. The survey included questions regarding respondents' personal drug and alcohol experience and behaviour, opinions on drug policy and legislation, availability of drugs and alcohol, injury and harm from drugs and alcohol, and attitudes towards the use of alcohol and other drugs. The drugs covered included: tobacco/cigarettes, alcohol, pain-killers/pain-relievers and opioids, tranquillisers, heroin, methadone, inhalants, ketamine, GHB, ecstasy, hallucinogens, cocaine, meth/amphetamines, cannabis/marijuana, synthetic cannabis, other psychoactive substances, and steroids. Demographic and background variables included: state of residence, age, sex, marital status, self-assessed health status, sexuality, Indigenous status, country of birth, language spoken at home, employment status, occupation, level of education, income, index of socio-economic advantage and disadvantage, remoteness area and household composition.

This study is the seventh in a series of national household surveys to examine current awareness, attitudes and behaviour related to drugs and drug problems, usage of drugs, and to assess changes in these attitudes and usage over the period 1985-2001. The seven earlier studies are Social Issues in Australia, 1985; the National Campaign Against Drug Abuse Social Issues Survey, 1988; the National Campaign Against Drug Abuse Social Issues Survey, 1991; the National Campaign Against Drug Abuse Social Issues Survey, 1993; the National Drug Strategy Household Survey, 1995; the National Drug Strategy Household Survey, 1998; and the National Drug Strategy Household Survey, 2001. A supplement was also carried out targeting the urban Aboriginal and Torres Strait Islander populations in 1994. As with the previous surveys in the series, the questionnaire asked respondents about their degree of concern regarding various social issues and drugs. For the 'Drop & collect' sample, a sealed section of the questionnaire allowed respondents to indicate their usage of each drug without the interviewer being aware of their answers. For the Computer Assisted Telephone Interview (CATI) sample these sections were asked directly by the interviewer. The drugs covered were: tobacco/cigarettes, alcohol, pain killers/ analgesics, tranquillisers, steroids, barbiturates, cannabis, heroin, methadone, other opiates, amphetamines, cocaine, hallucinogens, LSD, ecstasy, GHB, ketamines and inhalants. Background variables include state, remoteness category, sex, age, marital status, indigenous status, country of birth, language spoken at home, employment status, occupation, educational attainment, income and index of socio-economic disadvantage, and household descriptions.

This study is the eighth in a series of national household surveys to examine current awareness, attitudes and behaviour related to drugs and drug problems, usage of drugs, and to assess changes in these attitudes and usage over the period 1985-2004. The seven earlier studies are Social Issues in Australia, 1985; the National Campaign Against Drug Abuse Social Issues Survey, 1988; the National Campaign Against Drug Abuse Social Issues Survey, 1991; the National Campaign Against Drug Abuse Social Issues Survey, 1993; the National Drug Strategy Household Survey, 1995; the National Drug Strategy Household Survey, 1998; and the National Drug Strategy Household Survey, 2001. A supplement was also carried out targeting the urban Aboriginal and Torres Strait Islander populations in 1994. As with the previous surveys in the series, the questionnaire asked respondents about their degree of concern regarding various social issues and drugs. For the 'Drop & collect' sample, a sealed section of the questionnaire allowed respondents to indicate their usage of each drug without the interviewer being aware of their answers. For the Computer Assisted Telephone Interview (CATI) sample these sections were asked directly by the interviewer. The drugs covered were: tobacco/cigarettes, alcohol, pain killers/ analgesics, tranquillisers, steroids, barbiturates, cannabis, heroin, methadone, other opiates, amphetamines, cocaine, hallucinogens, LSD, ecstasy, GHB, ketamines and inhalants. Background variables include state, remoteness category, sex, age, marital status, indigenous status, country of birth, language spoken at home, employment status, occupation, educational attainment, income and index of socio-economic disadvantage, and household descriptions.

The PATH Study was launched in 2011 to inform the Food and Drug Administration's regulatory activities under the Family Smoking Prevention and Tobacco Control Act (TCA). The PATH Study is a collaboration between the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), and the Center for Tobacco Products (CTP), Food and Drug Administration (FDA). The study sampled over 150,000 mailing addresses across the United States to create a national sample of people who use or do not use tobacco. 45,971 adults and youth constitute the first (baseline) wave, Wave 1, of data collected by this longitudinal cohort study. These 45,971 adults and youth along with 7,207 "shadow youth" (youth ages 9 to 11 sampled at Wave 1) make up the 53,178 participants that constitute the Wave 1 Cohort. Respondents are asked to complete an interview at each follow-up wave. Youth who turn 18 by the current wave of data collection are considered "aged-up adults" and are invited to complete the Adult Interview. Additionally, "shadow youth" are considered "aged-up youth" upon turning 12 years old, when they are asked to complete an interview after parental consent. At Wave 4, a probability sample of 14,098 adults, youth, and shadow youth ages 10 to 11 was selected from the civilian, noninstitutionalized population (CNP) at the time of Wave 4. This sample was recruited from residential addresses not selected for Wave 1 in the same sampled Primary Sampling Unit (PSU)s and segments using similar within-household sampling procedures. This "replenishment sample" was combined for estimation and analysis purposes with Wave 4 adult and youth respondents from the Wave 1 Cohort who were in the CNP at the time of Wave 4. This combined set of Wave 4 participants, 52,731 participants in total, forms the Wave 4 Cohort. At Wave 7, a probability sample of 14,863 adults, youth, and shadow youth ages 9 to 11 was selected from the CNP at the time of Wave 7. This sample was recruited from residential addresses not selected for Wave 1 or Wave 4 in the same sampled PSUs and segments using similar within-household sampling procedures. This "second replenishment sample" was combined for estimation and analysis purposes with the Wave 7 adult and youth respondents from the Wave 4 Cohorts who were at least age 15 and in the CNP at the time of Wave 7. This combined set of Wave 7 participants, 46,169 participants in total, forms the Wave 7 Cohort. Please refer to the Restricted-Use Files User Guide that provides further details about children designated as "shadow youth" and the formation of the Wave 1, Wave 4, and Wave 7 Cohorts. Dataset 0002 (DS0002) contains the data from the State Design Data. This file contains 7 variables and 82,139 cases. The state identifier in the State Design file reflects the participant's state of residence at the time of selection and recruitment for the PATH Study. Dataset 1011 (DS1011) contains the data from the Wave 1 Adult Questionnaire. This data file contains 2,021 variables and 32,320 cases. Each of the cases represents a single, completed interview. Dataset 1012 (DS1012) contains the data from the Wave 1 Youth and Parent Questionnaire. This file contains 1,431 variables and 13,651 cases. Dataset 1411 (DS1411) contains the Wave 1 State Identifier data for Adults and has 5 variables and 32,320 cases. Dataset 1412 (DS1412) contains the Wave 1 State Identifier data for Youth (and Parents) and has 5 variables and 13,651 cases. The same 5 variables are in each State Identifier dataset, including PERSONID for linking the State Identifier to the questionnaire and biomarker data and 3 variables designating the state (state Federal Information Processing System (FIPS), state abbreviation, and full name of the state). The State Identifier values in these datasets represent participants' state of residence at the time of Wave 1, which is also their state of residence at the time of recruitment. Dataset 1611 (DS1611) contains the Tobacco Universal Product Code (UPC) data from Wave 1. This data file contains 32 variables and 8,601 cases. This file contains UPC values on the packages of tobacco products used or in the possession of adult respondents at the time of Wave 1. The UPC values can be used to identify and validate the specific products used by respondents and augment the analyses of the characteristics of tobacco products used

The Victorian Drug Household Survey (VDHS) was conducted as an extension to the fourth National Campaign Against Drugs and Alcohol (NCADA) National Drug Household Survey (NDHS). Prior to 1993, the NCADA NDHS had been conducted on three occasions: 1985, 1988 and 1991. The same questionnaire as used in the 1993 NDHS was the basis for this supplementary survey, although a number of new questions were added and others of broader national interest were dropped. The purpose of the VDHS was to provide information about what the Victorian community understands about drug issues and what Victorians see as priorities for government action in relation to drug issues. Also, it was intended to provide a baseline measure of community attitudes and knowledge from which to develop and evaluate the Victorian Drug Strategy. The main variables include: perception of drug(s) causing most deaths in Australia; perception of drug(s) causing most concern for the community generally; drug causing the most concern to the respondent personally; number of standard drinks considered to be a risk to health; personal use of licit and illicit drugs; attitudes towards licit and illicit drugs; knowledge of information about drugs and services available for users; reaction to measures used to limit or restrict use and sale of licit and illicit drugs; and where to allocate goverment funds in an effort to reduce drug abuse. Demographic variables include age, sex, location, employment status, marital status, country of birth and highest education level.